Xeris Pharmaceuticals Stock Retained Earnings
| XERS Stock | USD 4.56 0.01 0.22% |
Xeris Pharmaceuticals fundamentals help investors to digest information that contributes to Xeris Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Xeris Stock. The fundamental analysis module provides a way to measure Xeris Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Xeris Pharmaceuticals stock.
Xeris |
Xeris Pharmaceuticals Company Retained Earnings Analysis
Xeris Pharmaceuticals' Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Xeris Pharmaceuticals Retained Earnings | (671.86 M) |
Most of Xeris Pharmaceuticals' fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Xeris Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, Xeris Pharmaceuticals has a Retained Earnings of (671.86 Million). This is 172.14% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The retained earnings for all United States stocks is 107.2% higher than that of the company.
Xeris Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Xeris Pharmaceuticals' direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Xeris Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Xeris Pharmaceuticals by comparing valuation metrics of similar companies.Xeris Pharmaceuticals is currently under evaluation in retained earnings category among its peers.
Xeris Fundamentals
| Return On Equity | -6.17 | ||||
| Return On Asset | -0.0533 | ||||
| Profit Margin | (0.27) % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 874.08 M | ||||
| Shares Outstanding | 153.94 M | ||||
| Shares Owned By Insiders | 3.99 % | ||||
| Shares Owned By Institutions | 42.86 % | ||||
| Number Of Shares Shorted | 10.27 M | ||||
| Price To Book | 3.34 X | ||||
| Price To Sales | 3.46 X | ||||
| Revenue | 203.07 M | ||||
| Gross Profit | 166.24 M | ||||
| EBITDA | (13.99 M) | ||||
| Net Income | (54.84 M) | ||||
| Cash And Equivalents | 111.55 M | ||||
| Cash Per Share | 0.82 X | ||||
| Total Debt | 271.45 M | ||||
| Debt To Equity | 1.87 % | ||||
| Current Ratio | 2.50 X | ||||
| Book Value Per Share | (0.20) X | ||||
| Cash Flow From Operations | (36.98 M) | ||||
| Short Ratio | 5.88 X | ||||
| Earnings Per Share | (0.37) X | ||||
| Target Price | 6.08 | ||||
| Number Of Employees | 394 | ||||
| Beta | 1.21 | ||||
| Market Capitalization | 703.51 M | ||||
| Total Asset | 323.06 M | ||||
| Retained Earnings | (671.86 M) | ||||
| Working Capital | 67.22 M | ||||
| Net Asset | 323.06 M |
About Xeris Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xeris Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xeris Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xeris Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.